文献速递临床试验与 GCP

延长间隔与标准间隔唑来膦酸给药对骨转移患者骨骼事件的影响:一项随机临床试验

Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2017-01-01

这项在美国269个学术和社区站点开展的随机、开放标签临床试验纳入1822例乳腺癌、前列腺癌或多发性骨髓瘤骨转移患者,比较每4周与每12周静脉给予唑来膦酸2年的效果。每12周组与每4周组在2年内至少发生1次骨骼相关事件的比例分别为28.6%与29.5%,风险差为-0.3%(单侧95%CI,-4%至∞),非劣效性检验P<.001。延长间隔可能是一个可接受的治疗选择。

要点

  • 每12周唑来膦酸在2年内骨骼相关事件风险不劣于每4周标准给药。
  • 两组疼痛评分、体能状态、颌骨坏死和肾功能不全发生率无显著差异。
  • 每12周组骨转换抑制程度较低(C末端肽水平较高)。

核心结论

  • 在乳腺癌、前列腺癌或多发性骨髓瘤骨转移患者中,与每4周标准给药相比,每12周给予唑来膦酸2年未导致骨骼事件风险增加。
  • 这种更长的给药间隔可能是一个可接受的治疗选择。

研究设计与样本

  • 随机、开放标签临床试验,在美国269个学术和社区站点开展。
  • 纳入1822例有至少1处骨受累的转移性乳腺癌、转移性前列腺癌或多发性骨髓瘤患者,2009年5月至2012年4月入组,随访于2014年4月结束。
  • 患者随机接受每4周(n=911)或每12周(n=911)静脉给予唑来膦酸,持续2年。

主要发现

  • 每4周组260例(29.5%)与每12周组253例(28.6%)患者在随机化后2年内发生至少1次骨骼相关事件,风险差-0.3%(单侧95%CI,-4%至∞),非劣效性P<.001。
  • 乳腺癌、前列腺癌或多发性骨髓瘤患者中,每4周组与每12周组骨骼相关事件比例无显著差异。
  • 两组疼痛评分、体能状态评分、颌骨坏死发生率和肾功能不全发生率无显著差异。
  • 两组骨骼疾病率数值上相同,但每12周组骨转换抑制程度较低(C末端肽水平较高)。

关键数值与推荐

  • 主要终点为随机化后2年内至少发生1次骨骼相关事件(定义为临床骨折、脊髓压迫、骨放疗或骨手术)的患者比例,非劣效性界值为组间绝对差7%。
  • 疼痛采用简明疼痛量表评估(范围0-10,评分越高疼痛越重)。
  • 体能状态采用美国东部肿瘤协作组评分(范围0-4,评分越高残疾越重)。
  • 骨转换抑制在553例患者亚组中通过C末端肽水平评估。

临床怎么用

  • 原文结论指出,每12周给药可能是一个可接受的治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Zoledronic acid, a third-generation aminobisphosphonate, reduces the incidence of skeletal-related events and pain in patients with bone metastases. The optimal dosing interval for zoledronic acid is uncertain. OBJECTIVE: To determine whether zoledronic acid administered every 12 weeks is noninferior to zoledronic acid administered every 4 weeks. DESIGN, SETTING, PARTICIPANTS: Randomized, open-label clinical trial conducted at 269 academic and community sites in the United States. Patients (n = 1822) with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma who had at least 1 site of bone involvement were enrolled between May 2009 and April 2012; follow-up concluded in April 2014. INTERVENTIONS: Patients were randomized to receive zoledronic acid administered intravenously every 4 weeks (n = 911) vs every 12 weeks (n = 911) for 2 years. MAIN OUTCOMES AND MEASURES: The primary end point was the proportion of patients having at least 1 skeletal-related event (defined as clinical fracture, spinal cord compression, radiation to bone, or surgery involving bone) within 2 years after randomization and a between-group absolute difference of 7% as the noninferiority margin. Secondary end points included the proportion of patients with at least 1 skeletal-related event by disease type, pain as assessed by the Brief Pain Inventory (range, 0-10; higher scores indicate worse pain), Eastern Cooperative Oncology Group performance status (range, 0-4; higher scores indicate worse disability), incidence of osteonecrosis of the jaw, kidney dysfunction, skeletal morbidity rate (mean number of skeletal-related events per year), and, in a subset of 553 patients, suppression of bone turnover (assessed by C-terminal telopeptide levels). RESULTS: Among 1822 patients who were randomized (median age, 65 years; 980 [53.8%] women; 855 with breast cancer, 689 with prostate cancer, and 278 with multiple myeloma), 795 completed the study at 2 years. A total of 260 patients (29.5%) in the zoledronic acid every 4-week dosing group and 253 patients (28.6%) in the every 12-week dosing group experienced at least 1 skeletal-related event within 2 years of randomization (risk difference of -0.3% [1-sided 95% CI, -4% to ∞]; P < .001 for noninferiority). The proportions of skeletal-related events did not differ significantly between the every 4-week dosing group vs the every 12-week dosing group for patients with breast cancer, prostate cancer, or multiple myeloma. Pain scores, performance status scores, incidence of jaw osteonecrosis, and kidney dysfunction did not differ significantly between the treatment groups. Skeletal morbidity rates were numerically identical in both groups, but bone turnover was greater (C-terminal telopeptide levels were higher) among patients who received zoledronic acid every 12 weeks. CONCLUSIONS AND RELEVANCE: Among patients with bone metastases due to breast cancer, prostate cancer, or multiple myeloma, the use of zoledronic acid every 12 weeks compared with the standard dosing interval of every 4 weeks did not result in an increased risk of skeletal events over 2 years. This longer interval may be an acceptable treatment option. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00869206.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Himelstein AL, Foster JC, Khatcheressian JL, et al. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA. 2017. PMID: 28030702. doi:10.1001/jama.2016.19425

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。